Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Delgocitinib ointment for facial or neck atopic dermatitis after long-term topical steroids or tacrolimus
jRCTs031230063Completed
- Sponsor
- Torii Pharmaceutical
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of delgocitinib in atopic dermatitis (AD), sponsored by Torii Pharmaceutical. Primary endpoint: Treatment satisfaction with medication (TSQM-9) at 12 weeks. Started Jun 2023; status: completed.
02
Drugs
delgocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCTs031230063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031230063.